Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar;106(3):327-32.
doi: 10.1016/j.radonc.2013.02.002. Epub 2013 Feb 28.

Aortic dose constraints when reirradiating thoracic tumors

Affiliations

Aortic dose constraints when reirradiating thoracic tumors

Jaden D Evans et al. Radiother Oncol. 2013 Mar.

Abstract

Background and purpose: Improved radiation delivery and planning has allowed, in some instances, for the retreatment of thoracic tumors. We investigated the dose limits of the aorta wherein grade 5 aortic toxicity was observed after reirradiation of lung tumors.

Material and methods: In a retrospective analysis, 35 patients were identified, between 1993 and 2008, who received two rounds of external beam irradiation that included the aorta in the radiation fields of both the initial and retreatment plans. We determined the maximum cumulative dose to 1 cm(3) of the aorta (the composite dose) for each patient, normalized these doses to 1.8 Gy/fraction, and corrected them for long-term tissue recovery between treatments (NIDR).

Results: The median time interval between treatments was 30 months (range, 1-185 months). The median follow-up of patients alive at analysis was 42 months (range, 14-70 months). Two of the 35 patients (6%) were identified as having grade 5 aortic toxicities. There was a 25% rate of grade 5 aortic toxicity for patients receiving composite doses ≥120.0 Gy (vs. 0% for patients receiving <120.0 Gy) (P=0.047).

Conclusions: Grade 5 aortic toxicities were observed with composite doses ≥120.0 Gy (NIDR ≥90.0 Gy) to 1cm(3) of the aorta.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest Notification: The authors declare no conflicts of interest

Figures

Fig. 1
Fig. 1
Proportion of patients who did or did not develop aortic toxicity at defined composite doses. (A) Treatment of 1 cm3 of aorta to ≥120 Gy (without normalization of isoeffective dose or correction for aortic recovery), produced aortic toxicity in 25% of patients (P=0.047 vs. raw dose <120 Gy). (B) Treatment of 1 cm3 of aorta to ≥90 Gy (when the dose had been normalized to 1.8 Gy/fraction and corrected for long-term aortic recovery) resulted in aortic toxicity in 29% of patients (P=0.035 vs. NIDR <90 Gy).
Fig. 2
Fig. 2
Axial views of thoracic treatment plans for a woman who died of radiation-induced aortic damage. The aorta is contoured in yellow. (A) The initial plan involved treatment to 50.4 Gy (green isodose line; blue isodose line is 39.6 Gy). (B) The second plan involved treatment to 66.0 Gy (blue isodose line; green isodose line is 69.0 Gy). (C) The composite plan illustrates a green hot spot in the aorta (arrow) that received 120.0 Gy. (D) Dose volume histogram for the composite plan. GTV, gross tumor volume.
Fig. 3
Fig. 3
Axial views of thoracic treatment plans for a man who died of radiation-induced aortic damage. The aorta is contoured in yellow. (A) The initial plan involved treatment to 60.4 Gy (blue isodose line; green isodose line is 59.0 Gy). (B) The second plan involved treatment to 63.0 Gy (blue isodose line; green isodose line is 68.0 Gy). (C) The composite plan illustrates a green hot spot in the aorta (arrow) that received 127.0 Gy. (D) Dose volume histogram for the composite plan. GTV, gross tumor volume.

Similar articles

Cited by

References

    1. Kramer GW, Gans S, Ullmann E, et al. Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys. 2004;58(5):1388–1393. - PubMed
    1. Baumann P, Nyman J, Hoyer M, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008;88(3):359–367. - PubMed
    1. Creach KM, Bradley JD, Mahasittiwat P, et al. Stereotactic body radiation therapy in the treatment of multiple primary lung cancers. Radiother Oncol. 2012;104(1):19–22. - PubMed
    1. Jeremic B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys. 2011;80:969–977. - PubMed
    1. van Baardwijk A, Tome WA, van Elmpt W, et al. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. Radiother Oncol. 2012;105(2):145–149. - PubMed

Publication types

LinkOut - more resources